Liu Lilong, Liu Zhenghao, Fan Lei, Yao Zhipeng, Hu Junyi, Hou Yaxin, Li Yang, Ding Yuhong, Kuang Yingchun, Chen Ke, Hao Yi, Liu Zheng
Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Department of Urology, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, China.
Elife. 2025 Sep 10;13:RP95326. doi: 10.7554/eLife.95326.
Immunogenic cell death (ICD) is a type of cell death sparking adaptive immune responses that can reshape the tumor microenvironment. Exploring key ICD-related genes in bladder cancer (BLCA) could enhance personalized treatment. The Cancer Genome Atlas (TCGA) BLCA patients were divided into two ICD subtypes: ICD-high and ICD-low. High ICD expression linked to increased immune cell infiltration and longer survival, but with potentially suppressed immune function. The high ICD group responded better to PD1-targeted therapy. A risk-scoring model with four ICD-related genes (CALR, IL1R1, IFNB1, IFNG) was validated across TCGA, GEO datasets, and tissue samples, showing higher risk score correlated with weaker anti-tumor immune function, more tumor-promoting elements, lower immunotherapy response rates, and shorter patient survival. This study connects ICD-related genes to BLCA prognosis and immune infiltration, offering a vital tool for personalized treatment guidance.
免疫原性细胞死亡（ICD）是一种引发适应性免疫反应的细胞死亡类型，可重塑肿瘤微环境。探索膀胱癌（BLCA）中与ICD相关的关键基因可加强个性化治疗。癌症基因组图谱（TCGA）中的BLCA患者被分为两种ICD亚型：高ICD和低ICD。高ICD表达与免疫细胞浸润增加和更长生存期相关，但免疫功能可能受到抑制。高ICD组对PD1靶向治疗反应更好。一个包含四个与ICD相关基因（CALR、IL1R1、IFNB1、IFNG）的风险评分模型在TCGA、GEO数据集和组织样本中得到验证，显示较高的风险评分与较弱的抗肿瘤免疫功能、更多的肿瘤促进因素、较低的免疫治疗反应率以及较短的患者生存期相关。本研究将与ICD相关的基因与BLCA的预后和免疫浸润联系起来，为个性化治疗指导提供了重要工具。
